Overview

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF). Hu3F8 plus GM-CSF could prevent your neuroblastoma from growing, but it could also cause side effects.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

Y-mAbs Therapeutics

Treatments:

Isotretinoin